The immune checkpoint inhibitor avelumab increases aortic inflammation on [18F]FDG PET/CT: A retrospective cohort study
Year: 2025
Type: article
Language: en
Topic: Cancer Immunotherapy and Biomarkers
Authors and affiliations:
raw_author_name: Anniek Strijdhorst
raw_affiliation_strings: Amsterdam Cardiovascular Sciences, Atherosclerosis & Ischemic Syndromes, Amsterdam, The Netherlands
Amsterdam University Medical Center, location University of Amsterdam, Department of Vascular Medicine, Amsterdam, The Netherlands
Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, The Netherlands
raw_author_name: Reindert F. Oostveen
raw_affiliation_strings: Amsterdam Cardiovascular Sciences, Atherosclerosis & Ischemic Syndromes, Amsterdam, The Netherlands
Amsterdam University Medical Center, location University of Amsterdam, Department of Vascular Medicine, Amsterdam, The Netherlands
raw_author_name: Mark P.A. Schilder
raw_affiliation_strings: Amsterdam University Medical Center, location University of Amsterdam, Department of Vascular Medicine, Amsterdam, The Netherlands
raw_author_name: Arthur J.A.T. Braat
raw_affiliation_strings: Department of Nuclear Medicine, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands
raw_author_name: Youssef Chahid
raw_affiliation_strings: Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
raw_author_name: Damini Dey
raw_affiliation_strings: Department of Medicine (Division of Artificial Intelligence), Cedars-Sinai Medical Center, Los Angeles, California, United States of America
raw_author_name: Nordin M.J. Hanssen
raw_affiliation_strings: Amsterdam Cardiovascular Sciences, Atherosclerosis & Ischemic Syndromes, Amsterdam, The Netherlands
Amsterdam University Medical Center, location University of Amsterdam, Department of Vascular Medicine, Amsterdam, The Netherlands
raw_author_name: Hanneke W.M. van Laarhoven
raw_affiliation_strings: Amsterdam University Medical Center, location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands
Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, The Netherlands
raw_author_name: Anne W. van Schijndel
raw_affiliation_strings: Department of Cardiology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands
Department of Intensive Care, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands
raw_author_name: Tom T.P. Seijkens
raw_affiliation_strings: Division of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands
raw_author_name: Piotr J. Slomka
raw_affiliation_strings: Department of Medicine (Division of Artificial Intelligence), Cedars-Sinai Medical Center, Los Angeles, California, United States of America
raw_author_name: Erik S.G. Stroes
raw_affiliation_strings: Amsterdam Cardiovascular Sciences, Atherosclerosis & Ischemic Syndromes, Amsterdam, The Netherlands
Amsterdam University Medical Center, location University of Amsterdam, Department of Vascular Medicine, Amsterdam, The Netherlands
raw_author_name: Margot Tesselaar
raw_affiliation_strings: Division of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands
raw_author_name: Hein J. Verberne
raw_affiliation_strings: Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
raw_author_name: Nick van Es
raw_affiliation_strings: Amsterdam Cardiovascular Sciences, Atherosclerosis & Ischemic Syndromes, Amsterdam, The Netherlands
Amsterdam University Medical Center, location University of Amsterdam, Department of Vascular Medicine, Amsterdam, The Netherlands